仿制药-话题@MedSci

#仿制药#

261篇内容 | 5582人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1261354, encodeId=c90e1261354bd, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=度仿制药临床试验篡改数据等现象短期内难改善, objectType=article, longId=87136, objectId=c7728e13663, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7728e13663, replyNumber=0, likeNumber=107, createdTime=2017-01-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7728e13663, moduleTitle=度仿制药临床试验篡改数据等现象短期内难改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7728e13663)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261353, encodeId=0d871261353a5, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=艾伯维香菇蓝瘦！辉瑞阿达木单抗生物仿制药PF-06410293在III期临床获得成功, objectType=article, longId=87131, objectId=d5598e13167, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5598e13167, replyNumber=0, likeNumber=73, createdTime=2017-01-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5598e13167, moduleTitle=艾伯维香菇蓝瘦！辉瑞阿达木单抗生物仿制药PF-06410293在III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5598e13167)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261352, encodeId=276e126135298, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, objectType=article, longId=85558, objectId=25048555835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25048555835, replyNumber=0, likeNumber=80, createdTime=2016-12-28, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25048555835, moduleTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25048555835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261351, encodeId=68181261351ab, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=我国仿制药渐入国际主流市场一致性评价成关键, objectType=article, longId=85438, objectId=66b685438a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66b685438a4, replyNumber=0, likeNumber=80, createdTime=2016-12-26, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66b685438a4, moduleTitle=我国仿制药渐入国际主流市场一致性评价成关键, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66b685438a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261350, encodeId=372912613504c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=JAMA：ERBB2(HER2)阳性转移性乳腺癌治疗中，曲妥珠单抗生物仿制药的效果与曲妥珠单抗的效果等效吗？, objectType=article, longId=83429, objectId=1e488342901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e488342901, replyNumber=0, likeNumber=59, createdTime=2016-12-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e488342901, moduleTitle=JAMA：ERBB2(HER2)阳性转移性乳腺癌治疗中，曲妥珠单抗生物仿制药的效果与曲妥珠单抗的效果等效吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e488342901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261349, encodeId=efe91261349bf, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=2016AES立场声明——仿制药替代抗癫痫药发布, objectType=article, longId=79231, objectId=a26de923100, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a26de923100, replyNumber=0, likeNumber=26, createdTime=2016-10-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a26de923100, moduleTitle=2016AES立场声明——仿制药替代抗癫痫药发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a26de923100)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261348, encodeId=2758126134800, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=重磅！FDA批准美国市场阿达木单抗生物仿制药Amjevita, objectType=article, longId=78705, objectId=3d06e87059c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d06e87059c, replyNumber=0, likeNumber=0, createdTime=2016-09-29, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d06e87059c, moduleTitle=重磅！FDA批准美国市场阿达木单抗生物仿制药Amjevita, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d06e87059c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261347, encodeId=fc9e126134ef6, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=喜讯！默沙东与三星依那西普生物仿制药Brenzys获加拿大卫生部批准, objectType=article, longId=77800, objectId=ebc8e780028, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebc8e780028, replyNumber=0, likeNumber=87, createdTime=2016-09-20, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebc8e780028, moduleTitle=喜讯！默沙东与三星依那西普生物仿制药Brenzys获加拿大卫生部批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebc8e780028)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261346, encodeId=d5281261346bc, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=2018年底前须完成仿制药一致性评价品种目录公布啦！, objectType=article, longId=75432, objectId=0f4de5432ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f4de5432ce, replyNumber=0, likeNumber=53, createdTime=2016-08-20, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f4de5432ce, moduleTitle=2018年底前须完成仿制药一致性评价品种目录公布啦！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f4de5432ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261345, encodeId=024e126134555, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=原研药和仿制药的临床评价, objectType=article, longId=74012, objectId=c522e401214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c522e401214, replyNumber=0, likeNumber=57, createdTime=2016-07-30, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c522e401214, moduleTitle=原研药和仿制药的临床评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c522e401214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261344, encodeId=fc9c126134478, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据, objectType=article, longId=73839, objectId=0b9ee38391d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9ee38391d, replyNumber=0, likeNumber=75, createdTime=2016-07-28, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9ee38391d, moduleTitle=又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9ee38391d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261343, encodeId=303b12613433e, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=生物仿制药ABP 980与曲妥珠单抗具有可比性, objectType=article, longId=73516, objectId=3333e3516ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3333e3516ba, replyNumber=0, likeNumber=62, createdTime=2016-07-24, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3333e3516ba, moduleTitle=生物仿制药ABP 980与曲妥珠单抗具有可比性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3333e3516ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261342, encodeId=f3fc1261342e0, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=安进危险！诺华 Enbrel仿制药获FDA专家委员会支持批准, objectType=article, longId=73506, objectId=5ee6e3506dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ee6e3506dc, replyNumber=0, likeNumber=99, createdTime=2016-07-24, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ee6e3506dc, moduleTitle=安进危险！诺华 Enbrel仿制药获FDA专家委员会支持批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ee6e3506dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261341, encodeId=0c5f1261341e7, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=阿斯利康叫板FDA，要求终止批准瑞舒伐他汀仿制药, objectType=article, longId=72832, objectId=3775e28324d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3775e28324d, replyNumber=0, likeNumber=83, createdTime=2016-07-16, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3775e28324d, moduleTitle=阿斯利康叫板FDA，要求终止批准瑞舒伐他汀仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3775e28324d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261339, encodeId=b46b12613393a, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=单单中国，美国的仿制药企业也在为参比制剂而斗争！, objectType=article, longId=71399, objectId=7e4de13990f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e4de13990f, replyNumber=0, likeNumber=50, createdTime=2016-06-23, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e4de13990f, moduleTitle=单单中国，美国的仿制药企业也在为参比制剂而斗争！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e4de13990f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261340, encodeId=5805126134075, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=IMS：这些年，FDA批准的中国仿制药Top5, objectType=article, longId=71402, objectId=0ab9e14028c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ab9e14028c, replyNumber=0, likeNumber=0, createdTime=2016-06-23, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ab9e14028c, moduleTitle=IMS：这些年，FDA批准的中国仿制药Top5, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ab9e14028c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261338, encodeId=8391126133833, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=ASCO 2016：赫赛汀生物仿制药或可有效治疗HER2阳性的乳腺癌患者, objectType=article, longId=70016, objectId=04a8e0016c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04a8e0016c5, replyNumber=0, likeNumber=0, createdTime=2016-06-07, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04a8e0016c5, moduleTitle=ASCO 2016：赫赛汀生物仿制药或可有效治疗HER2阳性的乳腺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04a8e0016c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261337, encodeId=cc16126133e3c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA受理默沙东Remicade（类克）生物仿制药上市申请, objectType=article, longId=69255, objectId=ba9b69255bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba9b69255bf, replyNumber=0, likeNumber=58, createdTime=2016-05-27, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba9b69255bf, moduleTitle=FDA受理默沙东Remicade（类克）生物仿制药上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba9b69255bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261336, encodeId=cd1e1261336de, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA批准首批仿制药瑞舒伐他汀用于治疗高甘油三脂和高LDL, objectType=article, longId=67373, objectId=b0716e3734a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0716e3734a, replyNumber=0, likeNumber=82, createdTime=2016-05-02, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0716e3734a, moduleTitle=FDA批准首批仿制药瑞舒伐他汀用于治疗高甘油三脂和高LDL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0716e3734a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261335, encodeId=b899126133520, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=已确诊RA的目标治疗：新型靶向疗法和生物仿制药时代的挑战和机遇, objectType=article, longId=64849, objectId=f23164849d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f23164849d6, replyNumber=0, likeNumber=56, createdTime=2016-03-17, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f23164849d6, moduleTitle=已确诊RA的目标治疗：新型靶向疗法和生物仿制药时代的挑战和机遇, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f23164849d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

仿制药

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#仿制药#

度仿制药临床试验篡改数据等现象短期内难改善

2017-01-11

zhaojie88 (审核中...)

前往app查看评论内容

#仿制药#

艾伯维香菇蓝瘦！辉瑞阿达木单抗生物仿制药PF-06410293在III期临床获得成功

2017-01-11

zhaojie88 (审核中...)

前往app查看评论内容

#仿制药#

辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点

2016-12-28

zhaojie88 (审核中...)

前往app查看评论内容

#仿制药#

我国仿制药渐入国际主流市场一致性评价成关键

2016-12-26

zhaojie88 (审核中...)

前往app查看评论内容

#仿制药#

JAMA：ERBB2(HER2)阳性转移性乳腺癌治疗中，曲妥珠单抗生物仿制药的效果与曲妥珠单抗的效果等效吗？

2016-12-03

drwjr (审核中...)

前往app查看评论内容

#仿制药#

2016AES立场声明——仿制药替代抗癫痫药发布

2016-10-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

重磅！FDA批准美国市场阿达木单抗生物仿制药Amjevita

2016-09-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

喜讯！默沙东与三星依那西普生物仿制药Brenzys获加拿大卫生部批准

2016-09-20

drwjr (审核中...)

前往app查看评论内容

#仿制药#

2018年底前须完成仿制药一致性评价品种目录公布啦！

2016-08-20

drwjr (审核中...)

前往app查看评论内容

#仿制药#

原研药和仿制药的临床评价

2016-07-30

drwjr (审核中...)

前往app查看评论内容

#仿制药#

又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据

2016-07-28

drwjr (审核中...)

前往app查看评论内容

#仿制药#

生物仿制药ABP 980与曲妥珠单抗具有可比性

2016-07-24

drwjr (审核中...)

前往app查看评论内容

#仿制药#

安进危险！诺华 Enbrel仿制药获FDA专家委员会支持批准

2016-07-24

drwjr (审核中...)

前往app查看评论内容

#仿制药#

阿斯利康叫板FDA，要求终止批准瑞舒伐他汀仿制药

2016-07-16

drwjr (审核中...)

前往app查看评论内容

#仿制药#

单单中国，美国的仿制药企业也在为参比制剂而斗争！

2016-06-23

drwjr (审核中...)

前往app查看评论内容

#仿制药#

IMS：这些年，FDA批准的中国仿制药Top5

2016-06-23

drwjr (审核中...)

前往app查看评论内容

#仿制药#

ASCO 2016：赫赛汀生物仿制药或可有效治疗HER2阳性的乳腺癌患者

2016-06-07

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA受理默沙东Remicade（类克）生物仿制药上市申请

2016-05-27

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA批准首批仿制药瑞舒伐他汀用于治疗高甘油三脂和高LDL

2016-05-02

drwjr (审核中...)

前往app查看评论内容

#仿制药#

已确诊RA的目标治疗：新型靶向疗法和生物仿制药时代的挑战和机遇

2016-03-17

科室
- - 订阅+
  - 更多科室
工具
服务